Alogabat
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angelman Syndrome
Conditions
Angelman Syndrome
Trial Timeline
Jul 27, 2023 → Dec 2, 2025
NCT ID
NCT05630066About Alogabat
Alogabat is a phase 2 stage product being developed by Roche for Angelman Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05630066. Target conditions include Angelman Syndrome.
What happened to similar drugs?
0 of 3 similar drugs in Angelman Syndrome were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05630066 | Phase 2 | Completed |
Competing Products
9 competing products in Angelman Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RO7248824 | Roche | Phase 1 | 29 |
| RO7248824 | Roche | Phase 1 | 29 |
| ION582 | Ionis Pharmaceuticals | Phase 1/2 | 36 |
| ION582 + Placebo | Ionis Pharmaceuticals | Phase 3 | 44 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 3 | 38 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 3 | 41 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 2 | 36 |
| GTX-102 | Ultragenyx Pharmaceutical | Phase 1/2 | 26 |
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 | 29 |